# Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

> **NCT00413777** · PHASE2 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 46 (actual)

## Conditions studied

- Polycystic Kidney, Autosomal Dominant

## Interventions

- **DRUG:** Tolvaptan

## Key facts

- **NCT ID:** NCT00413777
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2017-07-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00413777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00413777, "Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT00413777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*